Hu L, Zheng C, Xu B, Tang W, Li H
Sci Rep. 2025; 15(1):7306.
PMID: 40025077
PMC: 11873059.
DOI: 10.1038/s41598-025-91404-2.
Liu Y, Li H, Chai D, Lian B, Bai Z, Gao Y
Transl Oncol. 2025; 53:102210.
PMID: 39874729
PMC: 11810844.
DOI: 10.1016/j.tranon.2024.102210.
Yang L, Song L, Zhang L, Yang Y, Zhang Y
J Multidiscip Healthc. 2025; 18:369-379.
PMID: 39866346
PMC: 11766289.
DOI: 10.2147/JMDH.S480476.
Huang G, Yu Y, Su H, Gan H, Chu L
Ann Med. 2025; 57(1):2447917.
PMID: 39847423
PMC: 11758802.
DOI: 10.1080/07853890.2024.2447917.
Shi L, Jiang J, Zhai J
Transl Cancer Res. 2025; 13(12):6675-6687.
PMID: 39816543
PMC: 11730692.
DOI: 10.21037/tcr-24-1077.
Cross-cultural adaptation of the simple Chinese version of the medication adherence reasons scale in patients undergoing adjuvant endocrine therapy for breast cancer.
Xu L, Li P, Hu Y, Xing W, Qiu J, Zhang X
BMC Cancer. 2025; 25(1):41.
PMID: 39780104
PMC: 11707837.
DOI: 10.1186/s12885-024-13382-4.
Epidemiology of breast cancer in Chinese women from 1990 to 2021: a systematic analysis and comparison with the global burden.
Long Z, Qiu Y, Long Z, Jin Z
BMC Cancer. 2025; 25(1):3.
PMID: 39757149
PMC: 11702233.
DOI: 10.1186/s12885-024-13336-w.
Pivotal Role of miRNA-lncRNA Interactions in Human Diseases.
Pooresmaeil F, Azadi S, Hasannejad-Asl B, Takamoli S, Bolhassani A
Mol Biotechnol. 2024; .
PMID: 39673006
DOI: 10.1007/s12033-024-01343-y.
Cancer situation in China: an analysis based on the global epidemiological data released in 2024.
Diao X, Guo C, Jin Y, Li B, Gao X, Du X
Cancer Commun (Lond). 2024; 45(2):178-197.
PMID: 39659114
PMC: 11833671.
DOI: 10.1002/cac2.12627.
Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects.
Zhu R, Ni J, Ren J, Li D, Xu J, Yu X
Front Oncol. 2024; 14:1464125.
PMID: 39605897
PMC: 11598703.
DOI: 10.3389/fonc.2024.1464125.
PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer.
Jia Y, Zhang J, Shi Y, Dong G, Guo X, Tong Z
Front Cell Dev Biol. 2024; 12:1430310.
PMID: 39469113
PMC: 11513371.
DOI: 10.3389/fcell.2024.1430310.
Development and validation of the NCC-BC-A scale to assess patient-reported outcomes for breast cancer patients in China.
Ma F, Yan X, Guan X, Liu T
Cancer Innov. 2024; 3(6):e141.
PMID: 39430623
PMC: 11487329.
DOI: 10.1002/cai2.141.
Radiomic analysis of cohort-specific diagnostic errors in reading dense mammograms using artificial intelligence.
Tao X, Gandomkar Z, Li T, Brennan P, Reed W
Br J Radiol. 2024; 98(1165):75-88.
PMID: 39383202
PMC: 11652727.
DOI: 10.1093/bjr/tqae195.
Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer.
Chen C, Zhu J, Zhang C, Wang L, Li Y, Du M
Am J Case Rep. 2024; 25:e943936.
PMID: 39295126
PMC: 11421188.
DOI: 10.12659/AJCR.943936.
Cancer Burden and Attributable Risk Factors of Cancers in China: Epidemiological Insights and Comparisons With India.
Rahmat S, He Y
Cancer Control. 2024; 31:10732748241276674.
PMID: 39240012
PMC: 11380140.
DOI: 10.1177/10732748241276674.
Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.
Shao Z, Tong Z, Liu Q, Li W, Cai L, Shen K
Cancer Med. 2024; 13(15):e7408.
PMID: 39136200
PMC: 11320080.
DOI: 10.1002/cam4.7408.
CircRNA hsa_circ_0003528/miR-215 is considered a potential target for predictive prognosis and therapy for triple-negative breast cancer.
Chang R, Yu H, Li S, Pan J
Mol Biol Rep. 2024; 51(1):901.
PMID: 39126511
DOI: 10.1007/s11033-024-09808-8.
Use of ultrasound imaging Omics in predicting molecular typing and assessing the risk of postoperative recurrence in breast cancer.
Song X, Xu H, Wang X, Liu W, Leng X, Hu Y
BMC Womens Health. 2024; 24(1):380.
PMID: 38956552
PMC: 11218367.
DOI: 10.1186/s12905-024-03231-8.
A nomogram for predicting the risk of cancer-related cognitive impairment in breast cancer patients based on a scientific symptom model.
Zhou Z, Ren J, Liu Q, Li S, Xu J, Wu X
Sci Rep. 2024; 14(1):14566.
PMID: 38914627
PMC: 11196746.
DOI: 10.1038/s41598-024-65406-5.
Case report: From negative to positive: a remarkable journey of ER, PR and HER2 status in a patient with metastatic breast cancer.
Huang J, Liu L, Ding J
Front Oncol. 2024; 14:1381541.
PMID: 38737908
PMC: 11088233.
DOI: 10.3389/fonc.2024.1381541.